Glaucon Side Effects
Generic Name: epinephrine ophthalmic
Note: This document contains side effect information about epinephrine ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Glaucon.
For the Consumer
Applies to epinephrine ophthalmic: ophthalmic solution
Along with its needed effects, epinephrine ophthalmic (the active ingredient contained in Glaucon) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking epinephrine ophthalmic:Incidence not known
- Blurred vision or other changes in vision
For Healthcare Professionals
Applies to epinephrine ophthalmic: ophthalmic solution
Chronic ophthalmic application of epinephrine to aphakic patients may cause maculopathy in up to 28% of patients (macular edema, vascular spasm, hemorrhages), which can result in distorted vision, central scotoma, and/or loss of visual acuity. This maculopathy can reverse within six months upon drug withdrawal.
A single case of madarosis (loss of eyelashes) has been associated with topical epinephrine. After the therapy was discontinued, the lashes grew back.[Ref]
Ocular side effects have included stinging and burning, lacrimation, and local discomfort upon application in up to 62% of patients. Browache, eye pain/ache, conjunctival hyperemia, allergic lid reactions, mydriasis, blurry vision, photophobia have been reported. Ocular cicatrization, pemphigoid, loss of eyelashes, and maculopathy have been reported rarely. Prolonged use can cause corneal edema, refractoriness of superficial blood vessels to constrict, and deposition of brownish oxidation products of epinephrine in the palpebral conjunctiva.[Ref]
Cardiovascular side effects associated with ocularly applied epinephrine have rarely included palpitations, tachycardia, extrasystoles, premature ventricular depolarizations, cardiac arrhythmias, and hypertension.[Ref]
In general, systemic side effects after topical application of epinephrine to the eye are more likely if the corneum is damaged or permeability is increased by tonometry, surgery, inflammation, or topical application of a local anesthetic.[Ref]
1. Goldstein JH "Effects of drugs on cornea, conjunctiva, and lids." Int Ophthalmol Clin 11 (1971): 13-34
2. Mooney D "Pigmentation after long-term topical use of adrenaline compounds." Br J Ophthalmol 54 (1970): 823-6
3. Obstbaum SA, Galin MA, Poole TA "Topical epinephrine and cystoid macular edema." Ann Ophthalmol 8 (1976): 455-8
4. Spaeth GL "Nasolacrimal duct obstruction caused by topical epinephrine." Arch Ophthalmol 77 (1967): 355-7
5. Thomas JV, Gragoudas ES, Blair NP, Lapus JV "Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes." Arch Ophthalmol 96 (1978): 625-8
6. Kass MA, Stamper RL, Becker B "Madarosis in chronic epinephrine therapy." Arch Ophthalmol 88 (1972): 429-31
7. Henkind P, Friedman AH "External ocular pigmentation." Int Ophthalmol Clin 11 (1971): 87-111
8. Mahmood MA, Pillai S "Epinephrine staining of a soft contact lens. Case report." Arch Ophthalmol 105 (1987): 1021-2
9. Becker B, Montgomery SW, Kass MA, Shin DH "Increased ocular and systemic responsiveness to epinephrine in primary open-angle glaucoma." Arch Ophthalmol 95 (1977): 789-90
10. "Product Information. Epifrin Sterile Ophthalmic Solution (epinephrine)." Allergan Inc, Irvine, CA.
11. Fiore PM "Drug-induced ocular cicatrization." Int Ophthalmol Clin 29 (1989): 147-50
12. Cerasoli JR "Effects of drugs on the retina." Int Ophthalmol Clin 11 (1971): 121-35
13. Mackool RJ, Muldoon T, Fortier A, Nelson D "Epinephrine-induced cystoid macular edema in aphakic eyes." Arch Ophthalmol 95 (1977): 791-3
14. Wandel T, Spinak M "Toxicity of dipivalyl epinephrine." Ophthalmology 88 (1981): 259-60
15. Drance SM, Ross RA "The ocular effects of epinephrine." Surv Ophthalmol 14 (1970): 330-5
16. Kass MA, Mandell AI, Goldberg I, Paine JM, Becker B "Dipivefrin and epinephrine treatment of elevated intraocular pressure: a comparative study." Arch Ophthalmol 97 (1979): 1865-6
17. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
18. Leon AS, Abrams WB "The role of catecholamines in producing arrhythmias." Am J Med Sci 262 (1971): 9-13
19. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
20. Korey MS, Hodapp E, Kass MA, Goldberg I, Gordon M, Becker B "Timolol and epinephrine: long-term evaluation of concurrent administration." Arch Ophthalmol 100 (1982): 742-5
21. Kolker AE, Becker B "Epinephrine maculopathy." Arch Ophthalmol 79 (1968): 552-62
22. Meyers EF, Ramirez RC, Boniuk I "Grand mal seizures after retrobulbar block." Arch Ophthalmol 96 (1978): 847
23. Gaspari AA "Contact allergy to ophthalmic dipivalyl epinephrine hydrochloride: demonstration by patch testing." Contact Dermatitis 28 (1993): 35-7
24. Alani SD, Alani MD "Allergic contact dermatits and conjunctivitis from epinephrine." Contact Dermatitis 2 (1976): 147-50
25. Fiore PM, Cinotti AA "Systemic effects of intraocular epinephrine during cataract surgery." Ann Ophthalmol 20 (1988): 23-5
26. Sonntag JR, Brindley GO, Shields MB, Arafat NI, Phelps CD "Timolol and epinephrine. Comparisin of efficacy and side effects." Arch Ophthalmol 97 (1979): 273-7
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.